Patterns and trends of mortality from metastatic colorectal cancer in Shanghai, China from 2005 to 2021: a population-based retrospective analysis

Author:

Cheng Xuelin,Zhou Jing,Chen Yichen,Zhao Yajun,Zheng Huichao,Wang Qizhe,Li XiaopanORCID,Jiang SunfangORCID

Abstract

Abstract Purpose Metastatic colorectal cancer (mCRC) is the leading cause of CRC deaths, however, the relative epidemiological research was insufficient. We aimed to analyze the patterns and trends of mortality of mCRC in Shanghai with a more complete system for monitoring the cause of death of the population and find potential methods to reduce the burden of CRC in China. Methods Mortality data from 2005 to 2021 of mCRC deaths were obtained from the mortality registration system in Shanghai. We analyzed the crude mortality rates, age-standardized mortality rates, and rates of years of life lost (YLL rates) of mCRC. In addition, the trends were quantified using Joinpoint Regression software. Results A total of 4,386 mCRC deaths were included, with 1,937 (44.16%) liver metastases and 1,061 (24.19%) lung metastases. The crude mortality rate and age-standardized mortality rate of mCRC were 9.09 per 105 person-years and 3.78 per 105 person-years, respectively. The YLL was 50,533.13 years, and the YLL rate was 104.67 per 105 person-years. The overall annual crude mortality rate of mCRC increased by 1.47% (95% CI 0.28–2.68%, P < 0.001) from 2005 to 2021. The crude mortality rate of mCRC increased by 3.20% per year (95% CI 1.80–4.70%, P < 0.001) from 2005 to 2013, but the trend of mortality growth remained stable from 2013 to 2021. The YLL rates remained stable between 2005 and 2021. Conclusions Population aging was the most likely factor responsible for the increase in CRC mortality in Pudong. Physical examinations and screenings for the elderly were possible reasons for reducing the burden of CRC in fast-growing regions.

Funder

Shanghai Public Health System Construction Three-year Action Plan Outstanding Youth Talent Training Program

Shanghai Municipal Program for Medical Leading Talents

Publisher

Springer Science and Business Media LLC

Reference50 articles.

1. Alwers E, Carr PR, Banbury B, Walter V, Chang-Claude J, Jansen L, Drew DA, Giovannucci E, Nan H, Berndt SI, Huang WY, Prizment A, Hayes RB, Sakoda LC, White E, Labadie J, Slattery M, Schoen RE, Diergaarde B, Van Guelpen B, Campbell PT, Peters U, Chan AT, Newcomb PA, Hoffmeister M, Brenner H (2021) Smoking behavior and prognosis after colorectal cancer diagnosis: a pooled analysis of 11 studies. JNCI Cancer Spectr. https://doi.org/10.1093/jncics/pkab077

2. Association COCOCMD (2019) Expert Consensus on multidisciplinary comprehensive treatment of lung metastasis from colorectal cancer (2018 edition). Chin J Clin Oncol 46:51–63. https://doi.org/10.3760/cma.j.cn112152-20200402-00295

3. Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ (2017) Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: results from TRIBE and FIRE-3 trials. Eur J Cancer 77:13–20. https://doi.org/10.1016/j.ejca.2017.02.020

4. Biller LH, Schrag D (2021) Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA 325:669–685. https://doi.org/10.1001/jama.2021.0106

5. Cardoso R, Guo F, Heisser T, De Schutter H, Van Damme N, Nilbert MC, Tybjerg AJ, Bouvier AM, Bouvier V, Launoy G, Woronoff AS, Cariou M, Robaszkiewicz M, Delafosse P, Poncet F, Walsh PM, Senore C, Rosso S, Lemmens V, MaG E, Tomšič S, Žagar T, De Munain L, Marques A, Marcos-Gragera R, Puigdemont M, Galceran J, Carulla M, Sánchez-Gil A, Chirlaque MD, Hoffmeister M, Brenner H (2022) Proportion and stage distribution of screen-detected and non-screen-detected colorectal cancer in nine European countries: an international, population-based study. Lancet Gastroenterol Hepatol 7:711–723. https://doi.org/10.1016/s2468-1253(22)00084-x

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3